Senti Bio receives Nasdaq deficiency notice for audit committee composition

Senti Biosciences, Inc.

On Oct 22, 2024, Nasdaq notified Senti Bio that its audit committee has only two members, violating Listing Rule 5605(c)(2)(A).
Vacancy resulted from Susan Berland’s resignation from the board effective June 11, 2024.
Cure period: until Dec 9, 2024 (since next annual meeting already held) or June 11, 2025, whichever earlier.
No immediate impact on listing or trading of SNTI common stock on Nasdaq Capital Market.
Company evaluating committee membership and intends to regain compliance before cure deadline.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.